The Institute of Organic Chemistry and Biochemistry of CAS

The Institute of Organic Chemistry and Biochemistry of the CAS (IOCB) is one of the leading institutions in Czech Republic and even Europe. It has 60 years of successful basic research in the field of organic chemistry, biochemistry, chemistry of natural products and theoretical chemistry. IOCB is mainly known for its contribution to medicinal chemistry. There have been more than 15 pharmaceutical treatments introduced to the market in collaboration with several partners that originated at the IOCB. The portfolio of antivirotics developed in collaboration with Catholic University in Leuven (Belgium) and Gilead Sciences, Inc. (USA) include TenofovirTM which is a medication successfully used for treating HIV infection (VireadTM, TruvadaTM, AtriplaTM, StriblidTM a CompleraTM).

IOCB Tech is a technology transfer office that was established at the IOCB in 2009 and is owned entirely by the IOCB institute. The office provides research expertise, IP and project management and commercialization. Furthermore, an integral part of IOCB Tech’s duties is the development of spin off companies based on IOCB’s research and technologies mainly in medicinal chemistry, biochemistry, organic synthesis and analytical chemistry. The current IOCB Tech portfolio contains number of projects related to different therapeutic or technology areas: diagnostics, drug development, therapeutics, oncology, neuroprotection, metabolic diseases, anti-inflammatory diseases. Another important duty of IOCB Tech is to build long term business relationships with leading pharmaceutical and diagnostic companies and investors. IOCB Tech, Inc. is also a project manager of the Centre for development of original drugs (TE01020028, TA CR).

For more information, please visit us at https://www.iocbtech.cz/